Abstract 75P
Background
Cancer immunotherapy is dependent on immunostimulation to reorganise the tumour microenvironment (TME) and to increase anti-tumour effects of immune cells. There are currently many immunostimulants applicable to cancer therapy, such as antibodies, molecular drugs and PAMP activators. Choice of immunostimulant may be key, but method of delivery of treatment is equally as important as different routes may stimulate different immune pathways. Despite of the rapid development of nucleic acid drugs in recent years, the effect of nucleic acid on tumor immunity needs to be further investigated. Polyinosinic:polycytidylic acid (poly I:C) is a synthetic double-stranded RNA analog that shows promise as an adjuvant in cancer vaccines or immunotherapies. Poly I:C is known to interact with Toll-like receptor 3 (TLR3) when taken up by endocytosis, but when directly transfected into cells, poly I:C stimulates retinoic acid-inducible gene I (RIG-I) instead.
Methods
Poly I:C was used to mimic anti-tumour response after nucleic acid administration. Murine 4T1 mammary tumour-bearing BALB/c mice were treated with poly I:C by electroporation (EP) or syringe injection (SI) and monitored for tumour growth. To determine whether poly I:C-activated immune pathways differed between delivery modes, RIG-I and TLR3 pathway inhibitors were used to inhibit poly I:C-induced anti-tumour effect in 4T1 tumour model.
Results
Our results showed that poly I:C EP treatment induced stronger tumour suppression effect and tumour-specific adaptive immune response than via SI. And that this EP-treated anti-tumour effect could be suppressed by both RIG-I and TLR3 pathway inhibitors, but not in SI, suggesting that treatment of poly I:C via different delivery modes do activate different immune pathways.
Conclusions
We have demonstrated that poly I:C could induce different anti-tumour effects dependent on treatment delivery method. Our results suggest that the effects of nucleic acid drugs may vary depending on how they are administered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Osaka University.
Funding
Osaka University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
56P - SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume
Presenter: Christa Dijkhuizen
Session: Poster session 09
57P - Metastasis organotropism: Unveiling associated proteins using network biology
Presenter: Margarida Carrolo
Session: Poster session 09
59P - Correlation of tumor microenvironment signature in advanced stage non-small cell lung cancer with EGFR mutation who received EGFR-TKIs
Presenter: Chaiyapong Ngamchokwathana
Session: Poster session 09
60P - Establishment and characterization of a novel lung adenocarcinoma cell line HX-JCJ harboring MET ex14 skipping mutation
Presenter: Xuejin Ou
Session: Poster session 09
61P - Next generation sequencing and its clinical utility in advanced cancer: Single institute experience from low-middle income country
Presenter: Amit Badola
Session: Poster session 09
62P - Prebiotics modulate gut microbiota-mediated T cell immunity to enhance sintilimab inhibition of lung cancer
Presenter: QIN YAN
Session: Poster session 09
63P - Addition of human chorionic gonadotropin to the current standard mobilization approach with granulocyte-colony stimulating factor increases overall survival in a murine model of peripheral blood stem cell transplantation: Are we far enough for therapy?
Presenter: Andrei Cismaru
Session: Poster session 09
64P - Developing novel therapeutics for bladder cancer leveraging drosophila models
Presenter: Takuya Moriguchi
Session: Poster session 09
65P - Ionizing radiation induces vascular smooth muscle cell senescence through activating NF-κB-CTCF-p16 pathway
Presenter: xuefeng zheng
Session: Poster session 09
66P - Exploring the radiobiology and dosimetry of targeted alpha therapy as a tool to optimize its clinical application: A preclinical study
Presenter: Maria Filomena Botelho
Session: Poster session 09